News

Targeted Oncology18h
Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer
In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...
Targeted Oncology1d
Dostarlimab Shows Response in Endometrial Cancer
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Healio1d
VIDEO: Future 'up in the air' for luveltamab tazevibulin as treatment for ovarian cancer
In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Healio1d
VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer
In this video, Ursula A. Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer.Findings from a phase 1/2a study of ...
mskcc.org4d
FDA Approves Avutometinib-Defactinib Combination for Treating Recurrent Low-Grade Serous Ovarian Cancer With a KRAS Mutation
Overall, 44% of patients with a KRAS mutation in the phase 2 trial saw their tumors shrink, according to findings Dr. Grisham presented at the Society of Gynecologic Oncology Annual Meeting in March ...